Get the Stockscreener App
30.32
1.40%
-0.43
After Hours:
30.32
Structure Therapeutics Inc Adr stock is traded at $30.32, with a volume of 772.28K.
It is down -1.40% in the last 24 hours and up +13.86% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$30.75
Open:
$30.94
24h Volume:
772.28K
Relative Volume:
0.92
Market Cap:
$1.77B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-13.66
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+8.44%
1M Performance:
+13.86%
6M Performance:
-15.99%
1Y Performance:
-26.44%
1-Day Range:
$30.04
$31.47
1-Week Range:
$27.64
$31.59
52-Week Range:
$23.50
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
30.32 | 1.77B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics (NASDAQ:GPCR) Trading 8.3% HigherShould You Buy? - MarketBeat
JPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Air T (NASDAQ:AIRT) Shares Cross Below 200-Day Moving Average – What’s Next? - Defense World
JPMorgan Chase & Co. Acquires 25,500 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Analysts Issue Forecasts for Kits Eyecare Q4 Earnings - Defense World
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - MarketBeat
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts - BNN Bloomberg
GAMMA Investing LLC Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Schrödinger Secures $150M Novartis Deal, Advances Three Clinical Programs for 2025 - StockTitan
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year LowShould You Sell? - MarketBeat
GPCR stock touches 52-week low at $25.89 amid market challenges - Investing.com Canada
Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpHere's What Happened - MarketBeat
Stifel analysts initiate Structure Therapeutics stock with buy rating By Investing.com - Investing.com Canada
State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year LowShould You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% HigherStill a Buy? - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc. - MarketBeat
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - MedCity News
Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Time to Buy? - Defense World
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's
Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6%Still a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Franklin Resources Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral obesity drug stock shows promise amid fierce competition - Investing.com
Here's Why VKTX Stock Plummeted 18% on Wednesday - Yahoo Finance
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year LowWhat's Next? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - Defense World
Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages - Defense World
Structure Therapeutics Advances Obesity Treatment Candidate - TipRanks
Structure Therapeutics Unveils Breakthrough Oral Obesity Drug, First-in-Class Amylin Agonist Shows Promise - StockTitan
Mcewen Mining Inc (MUX-N) QuotePress Release - The Globe and Mail
Structure Therapeutics' SWOT analysis: oral GLP-1 stock faces fierce competition - Investing.com
Market Factors: The biggest debatesand risksfor investors looking to outperform in 2025 - The Globe and Mail
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts - MarketBeat
Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Pier Capital LLC Buys 33,087 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Wellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):